Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome
about
Biofeedback for treatment of chronic idiopathic constipation in adultsNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsTreatment for constipation: new and old pharmacological strategiesBiomarkers to distinguish functional constipation from irritable bowel syndrome with constipation.Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.The impact of laxative use upon symptoms in patients with proven slow transit constipation.Clinical features of constipation in general practice in ItalyCurrent and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatmentsThe impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trialsSubtypes of irritable bowel syndrome based on abdominal pain/discomfort severity and bowel pattern.An exploration of the barriers to the confident diagnosis of irritable bowel syndrome: A survey among general practitioners, gastroenterologists and experts in five European countries.The relationship between primary headache and constipation in children and adolescents.Effect of a new synbiotic supplement on symptoms, stool consistency, intestinal transit time and gut microbiota in patients with severe functional constipation: a pilot randomized double-blind, controlled trial.The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burdenOptimal management of constipation associated with irritable bowel syndromeSubtypes of irritable bowel syndrome in children and adolescents.Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialRelationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation.Drugs and constipation in elderly in nursing homes: what is the relation?Advancing treatment options for chronic idiopathic constipation.Lack of familial aggregation in chronic constipation excluding irritable bowel syndrome: a population-based study.Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation.Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Abdominal Symptoms Are Common and Benefit from Biofeedback Therapy in Patients with Dyssynergic DefecationChronic Constipation and Constipation-Predominant IBS: Separate and Distinct Disorders or a Spectrum of Disease?Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population.Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.Normative values for stool frequency and form using Rome III diagnostic criteria for functional constipation in adults: systematic review with meta-analysisTreatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic AgentsAssessment of the Asian Neurogastroenterology and Motility Association Chronic Constipation Criteria: An Asian Multicenter Cross-sectional Study.Systematic review: the effects of fibre in the management of chronic idiopathic constipation.Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis.Meta-analysis: the epidemiology of noncardiac chest pain in the community.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Recent advances in the diagnosis of irritable bowel syndrome.Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros.
P2860
Q24197862-55150515-30BB-4388-9914-DC9118F222E9Q26748617-611A710F-7B31-4272-8E4B-60FE78964940Q27027346-5EEDB805-F3DA-49B2-8EC8-EE4AAEB308D8Q31099942-4CA07635-4CBA-4DFA-9372-FFAE2CEC7F2CQ33586854-5A26A464-0B83-42CE-8FE0-35515A66AB11Q33695627-E25FB803-7D3B-4B01-B31F-DE9955F2A734Q33958710-3BE86902-4C23-4664-9B96-617949CEAC6CQ34072074-6DD95C31-8AD0-4768-A55D-DB3F05318F9EQ34418679-745D79E8-2FF9-4B49-979B-6320E6D03D6EQ34478089-66BAB155-68AC-47F1-ADF2-09A1120B105BQ34660338-EACEF1C9-91D9-4E8C-9FAF-A00294437A6CQ34782198-175D65A2-36ED-4C52-9E38-874D9229471EQ35043139-2F29BA52-B6B5-45F8-BA60-0603DFDC54B0Q35044207-D9387EE0-AE51-457D-9DF4-921F2759DF8BQ35171727-4267F5A7-B6B8-42FA-B4BA-980F6832A861Q35219108-0B32FC18-99B8-4819-958B-03AC4192AF33Q35583291-CE696507-DA9E-4C5D-A097-F25FCDACB127Q35586543-55EAFC67-31D0-43FC-A121-9171AA4FF714Q35596948-F1454F0B-C7CD-4469-8C1F-724604157B6AQ35723125-7CB8E727-2146-41CE-8324-50C6B049CB27Q35804351-B51069CB-6EE3-470A-8C8E-F1412007C8D5Q35821327-D688E7CE-D17F-4EBE-BDA4-1E420DAE39EEQ35858864-C203D685-F8FC-4B57-BEA3-5843360FD842Q35919641-21289074-9B43-4FF0-8520-62C28950A59EQ35922325-1792AF77-BBC5-4285-811A-083A7011324CQ36426025-6A84901D-FA12-468E-A350-2E2A9DEBAC57Q36752007-D183D02A-B1BF-4B92-9C68-D541151C4A72Q36916631-DC2D1C64-26C6-431D-8196-F9D505E238AFQ37045712-0611E807-81AD-41D5-AF4C-6D2DBB70E65BQ37253910-67F4A49D-1F7F-49F8-86E0-BF1AC5EFA996Q37657104-B5D862A3-3191-4DB7-8BFC-F934F8D93BE6Q37657368-669306BF-DC77-477A-A5D5-7314973D0AE7Q37740026-EDC9307A-22D8-42ED-B02C-8D9ECFE4F919Q37844660-C87CAA24-B64D-431C-8623-B898AE570CDDQ37878858-770F238B-1A8A-4C60-92D2-A5A28A693E4AQ37880175-668C12EB-B598-40C9-8EA0-C7D7073024E4Q38086870-E8C5471B-3960-40D4-8949-027B349F2D92Q38236812-CB93B419-D476-49F4-AAD1-3199983816A7Q38545062-0DA8A0B2-8B50-4CEB-86AC-1FD58DCEF34DQ38696423-03259014-2BF5-4DC2-A6EC-55D94D47A17C
P2860
Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inability of the Rome III crit ...... btype irritable bowel syndrome
@en
Inability of the Rome III crit ...... type irritable bowel syndrome.
@nl
type
label
Inability of the Rome III crit ...... btype irritable bowel syndrome
@en
Inability of the Rome III crit ...... type irritable bowel syndrome.
@nl
prefLabel
Inability of the Rome III crit ...... btype irritable bowel syndrome
@en
Inability of the Rome III crit ...... type irritable bowel syndrome.
@nl
P2093
P2860
P356
P1476
Inability of the Rome III crit ...... btype irritable bowel syndrome
@en
P2093
Andrew D Feld
Marsha J Turner
Michael von Korff
Olafur S Palsson
Reuben K Wong
Rona L Levy
William E Whitehead
P2860
P304
P356
10.1038/AJG.2010.200
P407
P577
2010-05-25T00:00:00Z